Adjust Font Size:

Press Releases

Advanced Cell Technology's Research Featured in Scientific American, USA Today and Newsweek

Important Questions Raised about iPS cells, Reinforcing Unique Viability of ACT's Blastomere Technology

WORCESTER, Mass.-- (BUSINESS WIRE)--Advanced Cell Technology or "ACT” (OTCBB: ACTC - News announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek. The coverage highlights a recent paper in the journal Stem Cells co-authored by ACT lead by its Chief Scientific Officer, Dr. Robert Lanza MD, and its collaborators. The paper reports that iPS cells exhibit abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT's embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems.

The Scientific American article, "Cell-Off: Induced Pluripotent Stem Cells Fall Short of Potential Found in Embryonic Version" includes the following passage: "The act of reprogramming cells to make them as capable as ones from embryos apparently can result in aberrant cells that age and die abnormally, suggesting there is a long way to go to prove such cells are really like embryonic stem cells and can find use in therapies." The story is available here.

The USA Today article is headlined, "Stem Cell Articles Show Early Aging Abnormalities.” In the story, Maria Blasco, of the Spanish National Cancer Center of Madrid, who was not part of the study, is quoted as saying, "the authors [of the article] show that induced stem cells are not of the same 'quality' as embryonic stem cells, and that induced-derived cell types tend to age and die earlier than those derived from embryonic stem cells.” It is available here.

The Newsweek story, "Still No Truce in the Stem Cell Wars,” discusses the "bad news" heralded by ACT's study for theoretical uses for iPS cells with stem cells produced by adults. ACT's technology platform uses embryonic stem cells. The article is available here.

"This study, published in Stem Cells, highlights the challenges often faced in attempting to translate promising science into clinical results,” said William M. Caldwell, IV, Chairman and CEO of Advanced Cell. "We are currently working on a solution to the problems raised by this research, and hope to be able to provide details shortly. We believe this study further validates the need to commercialize our blastomere technology, which is still on schedule to begin clinical trials in humans during the 2010 third quarter.”

ACT's collaborators on the study published in Stem Cells were McLean Hospital/Harvard Medical School, the University of Illinois at Chicago, and Stem Cell & Regenerative Medicine International (SCRMI), a joint venture between ACT and Korean biotech firm CHA.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visithttp://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter endedSeptember 30, 2007.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contact:

Media:
Bill Douglass, 917-328-3126
or
Investors:
CEOcast, Inc. for Advanced Cell Technology
Dan Schustack, 212-732-4300

Press Contact


Bill Douglass
917-328-3126

Download PDF


02.16.10.pdf

To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat